At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PCVX Vaxcyte, Inc.
Pre-Mkt 10-14 08:18:28 EDT
66.80
-3.85
-5.45%
盘前67.13
+0.33+0.49%
08:12 EDT
High71.09Low66.63Vol2.65M
Open70.58D1 Closing70.65Amplitude6.31%
Mkt Cap10.44BTradable Cap9.89BTotal Shares156.22M
T/O179.22MT/O Rate1.79%Tradable Shares148.04M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Movement Alert｜Vaxcyte, Inc. Falls 5.08% in Regular Trading, Shares Pull Back After Vaccine Trial Gains
Market Focus  ·  03:21
Movement Alert｜Vaxcyte, Inc. Falls 5.08% in Regular Trading, Shares Pull Back After Vaccine Trial Gains
Moderna Stock Puts MRNA Cancer Vaccine Shares Back In Focus
Simply Wall St.  ·  10-13 07:36
Moderna Stock Puts MRNA Cancer Vaccine Shares Back In Focus
Cantor Fitzgerald Sticks to Their Buy Rating for Vaxcyte (PCVX)
TIPRANKS  ·  10-12 19:46
Cantor Fitzgerald Sticks to Their Buy Rating for Vaxcyte (PCVX)
Vaxcyte Price Target Announced at $120.00/Share by Cantor Fitzgerald
Dow Jones  ·  10-12 19:08
Vaxcyte Price Target Announced at $120.00/Share by Cantor Fitzgerald
Vaxcyte Bolsters Capital Structure with New Offerings
TIPRANKS  ·  10-10
Vaxcyte Bolsters Capital Structure with New Offerings
Vaxcyte: Closing of $1.15 Bln Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
THOMSON REUTERS  ·  10-10
Vaxcyte: Closing of $1.15 Bln Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte Closes USD 650 Million Convertible Senior Notes Offering
Reuters  ·  10-10
Vaxcyte Closes USD 650 Million Convertible Senior Notes Offering
Press Release: Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Convertible Senior Notes
Dow Jones  ·  10-10
Press Release: Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Convertible Senior Notes
Vaxcyte Inc Stock (PCVX) Moved Up by 9.47% on Oct 9: What Signal Does It Send?
TradingKey  ·  10-10
Vaxcyte Inc Stock (PCVX) Moved Up by 9.47% on Oct 9: What Signal Does It Send?
Sector Update: Healthcare
MT Newswires Live  ·  10-10
Sector Update: Healthcare
Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand
MT Newswires Live  ·  10-10
Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand
Movement Alert｜Vaxcyte, Inc. Intraday Rise 5.24%, Analysts Raise Price Targets After Positive Phase 3 Vaccine Data
Market Focus  ·  10-09
Movement Alert｜Vaxcyte, Inc. Intraday Rise 5.24%, Analysts Raise Price Targets After Positive Phase 3 Vaccine Data
Leerink Partners Reaffirms Their Buy Rating on Vaxcyte (PCVX)
TIPRANKS  ·  10-09
Leerink Partners Reaffirms Their Buy Rating on Vaxcyte (PCVX)
Portable MRI Maker Hyperfine's Q3 Prelim Revenue Beats Estimates; FY Outlook Reaffirmed
Reuters  ·  10-08
Portable MRI Maker Hyperfine's Q3 Prelim Revenue Beats Estimates; FY Outlook Reaffirmed
Vaxcyte SVP Finance, CAO Elvia Cowan Disposes of 19,000 Common Shares for $1,647,060
Reuters  ·  10-08
Vaxcyte SVP Finance, CAO Elvia Cowan Disposes of 19,000 Common Shares for $1,647,060
US Stocks on the MOVE-Halozyme, Moderna, Merck
Reuters  ·  10-08
US Stocks on the MOVE-Halozyme, Moderna, Merck
U.S. Stocks on the MOVE-Halozyme, BKV, AppFolio
Reuters  ·  10-08
U.S. Stocks on the MOVE-Halozyme, BKV, AppFolio
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
TIPRANKS  ·  10-07
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
U.S. Stocks on the MOVE-Intel, Vaxcyte, Constellation Brands
Reuters  ·  10-07
U.S. Stocks on the MOVE-Intel, Vaxcyte, Constellation Brands
Vaxcyte 7.412M share Spot Secondary priced at $64.00
TIPRANKS  ·  10-07
Vaxcyte 7.412M share Spot Secondary priced at $64.00

Introduction

Company Name.
Vaxcyte, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Issue price:
--